biostudies-literatureUnknown37(11)Ferreira JJ<h4>Background</h4>Inhibiting catechol-O-methyltransferase extends the plasma half-life of levodopa, potentially allowing physicians to optimize the levodopa regimen in patients with Parkinson's disease (PD) experiencing motor fluctuations.<h4>Objectives</h4>To evaluate the effects of once-daily opicapone on levodopa plasma pharmacokinetics and motor response when added to two different levodopa dosing regimens.<h4>Methods</h4>A total of 24 patients with PD and motor fluctuations were enrolled in an exploratory, open-label, modified cross-over trial. Participants first received levodopa/carbidopa 500/125 mg (five intakes) for 2 weeks and were then randomly assigned (1:1) to levodopa/carbidopa 400/100 mg given over either four or five daily intakes plus opicapone 50 mg for an additional 2 wMovement disorders : official journal of the Movement Disorder Society2272-2283https://www.ebi.ac.uk/biostudies/studies/S-EPMC9804871biostudies-literatureEffect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.PMC9804871Rocha JFGuimaraes BAntonini APoewe WFerreira JJMoreira JRascol OStocchi FSoares-da-Silva PfalseEffect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.<h4>Background</h4>Inhibiting catechol-O-methyltransferase extends the plasma half-life of levodopa, potentially allowing physicians to optimize the levodopa regimen in patients with Parkinson's disease (PD) experiencing motor fluctuations.<h4>Objectives</h4>To evaluate the effects of once-daily opicapone on levodopa plasma pharmacokinetics and motor response when added to two different levodopa dosing regimens.<h4>Methods</h4>A total of 24 patients with PD and motor fluctuations were enrolled in an exploratory, open-label, modified cross-over trial. Participants first received levodopa/carbidopa 500/125 mg (five intakes) for 2 weeks and were then randomly assigned (1:1) to levodopa/carbidopa 400/100 mg given over either four or five daily intakes plus opicapone 50 mg for an additional 2 w2022-01-01T00:00:00Z2022 Nov2025-04-22T04:23:27.377Z2025-04-05T21:02:17.57ZS-EPMC98048713605456210.1002/mds.29193